Gedeon Richter (RICHTER) Investor Presentation summary

Strategic vision and business segments

• Aims to be a leading European mid-pharma company, focusing on improving global health and quality of life as an independent entity.

• Operates in four main segments: Neuropsychiatry (CNS), Women's Healthcare (WHC), Biotechnology (BIO), and General Medicines (GM), with 2023 revenues of EUR 2.1bn+.

• Over 120 years of development, 11,600 employees, 8 manufacturing sites, and presence in 100+ countries.

• 93% of revenue comes from international sales, with a strong pan-European distribution network.

• Preparing for Vraylar loss of exclusivity (LoE) in 2029 by boosting non-Vraylar revenues and strengthening all business segments.

Neuropsychiatry (CNS)

• CNS segment leverages world-class early-phase R&D, focusing on original research and pipeline development in neuropsychiatry.

• Cariprazine (Vraylar) is a multi-billion USD blockbuster in the US, with LoE expected in September 2029.

• CNS revenues and EBIT have grown significantly, with a strong pipeline including several preclinical and clinical projects, many in partnership with AbbVie.

• New R&D collaboration with AbbVie in October 2024 to discover and develop novel neuropsychiatric treatments.

• Cariprazine is available in 66 countries, with new drug forms and expanded indications.

Women's Healthcare (WHC)

• WHC aims to be the No.1 player in Europe by 2030, targeting EUR 1bn+ sales and global expansion.

• Vertically integrated, with a broad portfolio covering contraception, fertility, endometriosis, and menopause.

• Strategic acquisitions and partnerships (e.g., Mithra, BCI) have expanded the innovative product pipeline and research capabilities.

• Leading provider of emergency contraception in Europe and expanding presence in LatAm, US, and China.

• WHC revenues have shown dynamic growth, supported by both legacy and innovative products.